DuChemBIO Co.,Ltd.
Financials
Valuation Metrics
DuChemBIO Co.,Ltd.'s Market Cap is ₩1738B. At end of 2025 it was ₩2712B. Ranked #885 of 2,405 in KR market (top 37%), #411 of 1,627 on KOSDAQ (top 25%), #28 of 94 in Health Care Equipment & Services (top 30%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 173.78B KRW | KR#885/2,405 Sec#28/94 |
| Revenue | 41.51B KRW | KR#1,894/2,405 Sec#54/94 |
| Net Income | 6.83B KRW | KR#1,097/2,405 Sec#33/94 |
| Total Assets | 77.60B KRW | KR#1,947/2,405 Sec#64/94 |
| Net Assets | 51.57B KRW | KR#1,884/2,405 Sec#59/94 |
| Employees | 141 | KR#1,365/2,405 Sec#46/94 |
| Value | ||
| P/E | 25.46x | KR#1,278/2,405 Sec#42/94 |
| P/B | 3.37x | KR#2,171/2,405 Sec#79/94 |
| P/S | 4.19x | KR#2,115/2,405 Sec#70/94 |
| EV/EBITDA | 19.89x | KR#1,044/2,405 Sec#34/94 |
| FCF Yield | 5.22% | KR#858/2,405 Sec#22/94 |
| Profitability | ||
| ROE | 13.24% | KR#405/2,405 Sec#16/94 |
| ROA | 8.80% | KR#360/2,405 Sec#20/94 |
| Op. Margin | 19.45% | KR#173/2,405 Sec#13/94 |
| Revenue Growth | 8.35% | KR#987/2,405 Sec#55/94 |
| Earnings Growth | -18.94% | KR#923/2,405 Sec#36/94 |
| Financial Health | ||
| Debt Ratio | 50.47% | KR#956/2,405 Sec#54/94 |
| Total Debt | 5.86B KRW | KR#1,748/2,405 Sec#62/94 |
| FCF | 9.07B KRW | KR#737/2,405 Sec#19/94 |
| Cash | 19.03B KRW | KR#1,273/2,405 Sec#36/94 |
| Current Ratio | 1.80x | KR#970/2,405 Sec#58/94 |
| Net Debt/EBITDA | -1.63x | KR#275/2,405 Sec#7/94 |
| Performance | ||
| 1Y Return | -33.48% | KR#1,520/2,405 Sec#49/94 |
| 1M Return | -16.32% | KR#1,658/2,405 Sec#68/94 |
| From 52W High | -52.23% | KR#1,272/2,405 Sec#47/94 |
| 1Y MDD | -53.42% | KR#1,107/2,405 Sec#41/94 |
| Trading | ||
| Volume | 94,639 shares | KR#654/2,405 Sec#25/94 |
| Trading Value | 581.8M KRW | KR#737/2,405 Sec#19/94 |
| Foreign Own. | 0.81% | KR#2,094/2,405 Sec#80/94 |
| Per Share | ||
| EPS | 240 KRW | KR#1,236/2,405 Sec#38/94 |
| BPS | 1,810 KRW | KR#2,111/2,405 Sec#73/94 |
Company Info
DuChemBio was established in 2002 for the development, manufacturing, and sales of radiopharmaceuticals for cancer and brain disease diagnosis and treatment, completing its KOSDAQ transfer listing in 2024. The company holds the largest number of PET-CT pharmaceuticals in Korea and operates 12 GMP-certified manufacturing facilities, achieving the top market share in major product categories. With a "First-in-Class" strategy for diagnostics and "Best-in-Class" for therapeutics, DuChemBio is striving to become a specialized radiopharmaceutical platform company in Asia. DuChemBio was established in 2002 and is headquartered in Mapo-gu, Seoul.